NCT07328100

Efficacy and Safety of Coenzyme I for Injection on Vascular Aging.

A Randomized, Double-blind, Parallel Controlled Clinical Trial to Evaluate the Efficacy of Coenzyme I for Injection in the Treatment of Vascular Aging（Pilot Stydy）

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Shanghai 10th People's Hospital · Academic / Other
• Sex: All
• Age: 40 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Emerging evidence identifies vascular aging independently predicting cardiovascular events, yet effective clinical interventions remain lacking. Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor whose levels decline with age, and preclinical studies suggest that boosting NAD+ can improve vascular function and structure. Preliminary clinical studies in healthy older adults indicate that supplementation with NAD+ precursors, such as nicotinamide riboside(NR) or nicotinamide mononucleotide (NMN), can reduce arterial stiffness as measured by pulse wave velocity (PWV). However, whether NAD+ supplementation can improve vascular endothelial function and exert anti-stiffening effects in patients who have already developed measurable arterial stiffness remains unknown. Based on this evidence, the investigator hypothesize that the Coenzyme I for Injection will reverse vascular aging in older adults with established arterial stiffening.

Conditions

• Vascular Aging
• NAD

Interventions

Type	Name	Description
DRUG	Coenzyme I for Injection	Subjects receive 7 consecutive days of intravenous infusion of Coenzyme I for injection.
DRUG	NaCl (placebo)	Subjects receive 7 consecutive days of intravenous infusion of NaCl(0.9%).

Timeline

• Start date: 2026-01-16
• Primary completion: 2027-06-30
• Completion: 2027-12-31
• First posted: 2026-01-08
• Last updated: 2026-01-08

Locations

1 site across 1 country: China